A number of molecular biomarkers have been selected as key factors for cancer immunotherapy, including programmed death ligand 1 (PD-L1), tumor mutation load (TMB), high microsatellite instability (MSI), and gene mutations [7]. This evidence concerns the gene CD274 and neoplasm.